| Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10269), 99-111, 2021 | 5538 | 2021 |
| Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial PM Folegatti, KJ Ewer, PK Aley, B Angus, S Becker, ... The Lancet 396 (10249), 467-478, 2020 | 2869 | 2020 |
| Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial MN Ramasamy, AM Minassian, KJ Ewer, AL Flaxman, PM Folegatti, ... The Lancet 396 (10267), 1979-1993, 2020 | 1743 | 2020 |
| Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four … M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10277), 881-891, 2021 | 1390 | 2021 |
| HIV vaccine candidate activation of hypoxia and the inflammasome in CD14+ monocytes is associated with a decreased risk of SIV mac251 acquisition M Vaccari, S Fourati, SN Gordon, DR Brown, M Bissa, L Schifanella, ... Nature medicine 24 (6), 847-856, 2018 | 67 | 2018 |
| Human basigin (CD147) does not directly interact with SARS-CoV-2 spike glycoprotein RJ Ragotte, D Pulido, FR Donnellan, G Gorini, H Davies, J Brun, ... bioRxiv, 2021 | 43 | 2021 |
| Regulatory and helper follicular T cells and antibody avidity to simian immunodeficiency virus glycoprotein 120 MJ Blackburn, M Zhong-Min, F Caccuri, K McKinnon, L Schifanella, ... The Journal of Immunology 195 (7), 3227-3236, 2015 | 43 | 2015 |
| Select gp120 V2 domain specific antibodies derived from HIV and SIV infection and vaccination inhibit gp120 binding to α4β7 S Lertjuthaporn, C Cicala, D Van Ryk, M Liu, J Yolitz, D Wei, F Nawaz, ... PLoS pathogens 14 (8), e1007278, 2018 | 33 | 2018 |
| Possible future monoclonal antibody (mAb)-based therapy against arbovirus infections G Sautto, N Mancini, G Gorini, M Clementi, R Burioni BioMed Research International 2013, 2013 | 25 | 2013 |
| The V2 loop of HIV gp120 delivers costimulatory signals to CD4+ T cells through Integrin α4β7 and promotes cellular activation and infection LR Goes, A Sajani, A Sivro, R Olowojesiku, JC Ray, I Perrone, J Yolitz, ... Proceedings of the National Academy of Sciences 117 (51), 32566-32573, 2020 | 18 | 2020 |
| The sudden death of Alaric I (c. 370–410 AD), the vanquisher of Rome: A tale of malaria and lacking immunity FM Galassi, R Bianucci, G Gorini, GM Paganotti, ME Habicht, FJ Rühli European journal of internal medicine 31, 84-87, 2016 | 17 | 2016 |
| Anti-V2 antibodies virus vulnerability revealed by envelope V1 deletion in HIV vaccine candidates IS de Castro, G Gorini, R Mason, J Gorman, M Bissa, MA Rahman, ... Iscience 24 (2), 102047, 2021 | 16 | 2021 |
| Engagement of monocytes, NK cells, and CD4+ Th1 cells by ALVAC-SIV vaccination results in a decreased risk of SIVmac251 vaginal acquisition G Gorini, S Fourati, M Vaccari, MA Rahman, SN Gordon, DR Brown, ... PLoS pathogens 16 (3), e1008377, 2020 | 16 | 2020 |
| RECOMBINANT GP120 PROTEIN WITH V1-LOOP DELETION G Franchini, T Cardozo, M Becerra-flores, S De, C Isabela, G Gorini, ... US Patent App. 17/285,453, 2021 | | 2021 |
| Correction: ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type L Schifanella, SW Barnett, M Bissa, V Galli, MN Doster, M Vaccari, ... PLoS pathogens 16 (4), e1008531, 2020 | | 2020 |
| ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type (vol 15, e1008121, 2019) L Schifanella, SW Barnett, M Bissa, V Galli, MN Doster, M Vaccari, ... PLOS PATHOGENS 16 (4), 2020 | | 2020 |
| Study of the Immune Correlates of Protection in Rhesus Macaques Vaccinated against Simian Immunodeficiency Virus G Gorini University of Cambridge, 2019 | | 2019 |
| A helical structure in the V2 domain of gp120 that localizes to the site of immune pressure in the RV144 vaccine trial is conserved in HIV and SIV envelopes S Lertjuthaporn, C Cicala, D Van Ryk, J Yolitz, D Wei, G Gorini, ... JOURNAL OF THE INTERNATIONAL AIDS SOCIETY 22, 20-20, 2019 | | 2019 |
| Abstracts of the HIV Research for Prevention Meeting, HIVR4P, 21-25 October, 2018, Madrid Z Shen, M Rodriguez-Garcia, M Patel, J Bodwell, C Wira, O Chuchuen, ... AIDS Research and Human Retroviruses 34 (S1), 1-407, 2018 | | 2018 |
| Select V2 Loop Antibodies Inhibit gp120 Binding to Integrin alpha (4) beta (7) S Lertjuthaporn, C Cicala, D Van Ryk, M Liu, J Yolitz, D Wei, G Gorini, ... AIDS RESEARCH AND HUMAN RETROVIRUSES 34, 29-29, 2018 | | 2018 |
